Floatz logo

VIXOTRIGINE

Trigeminal Neuralgia (TN)

BiogenSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Trigeminal Neuralgia (TN) cohort.

Asset / SponsorPhaseRating
Carbamazepine
Beijing Tiantan Hospital
Phase 4BB
LIDOCAINE
Beijing Tiantan Hospital
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Vanderbilt University Medical Center
Phase 4BB
Galcanezumab
Duke University
Phase 4BB
Oxcarbamezapine
Abbasi Shaheed Hospital
Phase 4BB

View all 34 →

Same molecule, other indications

VIXOTRIGINE is also rated in:

trigeminal neuralgiaDormant
B
Indicative ·
62 / 100
View asset →
sciaticaDormant
B
Indicative ·
58 / 100
View asset →
neuropathy, painfulDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →